Dr. Hemant S. Murthy, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 698
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME124262
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Jacksonville, FL
Medical groups
- Mayo Clinic Jacksonville (1,615 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 698
- Services billed
- 100,145
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 10,402 | 44 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 8,160 | 15 |
| Injection, fosaprepitant, 1 mg | 7,050 | 41 |
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 6,480 | 12 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 6,270 | 13 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 5,400 | 26 |
| Injection, nivolumab, 1 mg | 4,900 | 15 |
| Injection, oxaliplatin, 0.5 mg | 4,200 | 13 |
| Injection, paclitaxel protein-bound particles, 1 mg | 3,900 | 17 |
| Injection, denosumab, 1 mg | 2,040 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Jacksonville, FL | 67 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Jacksonville, FL | 28 |
| Jakafi (ruxolitinib phosphate) | 24 |
| Pantoprazole Sodium Other prescribers in Jacksonville, FL | 23 |
| Voriconazole | 22 |
| Eliquis (apixaban) Other prescribers in Jacksonville, FL | 19 |
| Prednisone Other prescribers in Jacksonville, FL | 18 |
| Fluconazole Other prescribers in Jacksonville, FL | 18 |
| Ursodiol Other prescribers in Jacksonville, FL | 16 |
| Penicillin V Potassium Other prescribers in Jacksonville, FL | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 40 payments worth $39,597 in total to this clinician.
| Kite Pharma, Inc. | $15,109 |
|---|---|
| Genzyme Corporation | $10,018 |
| Geron Corporation | $7,929 |
| Syndax Pharmaceuticals, Inc. | $3,616 |
| AbbVie Inc. | $725 |
| Daiichi Sankyo Inc. | $650 |
| Aimmune Therapeutics, Inc. | $625 |
| National Marrow Donor Program | $400 |
| Consulting Fee | $35,349 |
|---|---|
| Food and Beverage | $2,181 |
| Travel and Lodging | $1,668 |
| Compensation for services other than consulting (speaking, faculty) | $400 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Kite Pharma, Inc. May 4, 2025 | Consulting Fee Yescarta · CELLT Company’s description;4099111;GTF;10409093 | $13,340 |
| Genzyme Corporation Jun 7, 2025 | Consulting Fee | $9,296 |
| Geron Corporation Dec 18, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $7,313 |
| Syndax Pharmaceuticals, Inc. Dec 4, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $3,400 |
| AbbVie Inc. Dec 19, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $725 |
| Daiichi Sankyo Inc. Apr 10, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| Aimmune Therapeutics, Inc. Jun 10, 2025 | Consulting Fee VOWST · GI | $625 |
| Kite Pharma, Inc. May 2, 2025 | Travel and Lodging Yescarta · CELLT · travel to Tyson Corner, VA · in-kind Company’s description;4099232;GTF;10409093 | $515 |
| Genzyme Corporation Jun 7, 2025 | Travel and Lodging travel to Phiadelphia, PA · in-kind | $435 |
| Kite Pharma, Inc. May 2, 2025 | Travel and Lodging Yescarta · CELLT · travel to Tyson Corner, VA · in-kind Company’s description;4099847;GTF;10409093 | $427 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 19, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $725 |
| Geron Corporation Dec 18, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $7,313 |
| Geron Corporation Dec 18, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to MIAMI, FL | $16.94 |
| Syndax Pharmaceuticals, Inc. Dec 4, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $3,400 |
| Geron Corporation Nov 15, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to MIAMI, FL | $208 |
| Aimmune Therapeutics, Inc. Jun 10, 2025 | Consulting Fee VOWST · GI | $625 |
| Genzyme Corporation Jun 7, 2025 | Consulting Fee | $9,296 |
| Genzyme Corporation Jun 7, 2025 | Travel and Lodging travel to Phiadelphia, PA · in-kind | $435 |
| Genzyme Corporation Jun 7, 2025 | Travel and Lodging travel to Phiadelphia, PA | $66.00 |
| Kite Pharma, Inc. May 4, 2025 | Consulting Fee Yescarta · CELLT Company’s description;4099111;GTF;10409093 | $13,340 |
| Kite Pharma, Inc. May 2, 2025 | Travel and Lodging Yescarta · CELLT · travel to Tyson Corner, VA · in-kind Company’s description;4099232;GTF;10409093 | $515 |
| Kite Pharma, Inc. May 2, 2025 | Travel and Lodging Yescarta · CELLT · travel to Tyson Corner, VA · in-kind Company’s description;4099847;GTF;10409093 | $427 |
| Daiichi Sankyo Inc. Apr 10, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| National Marrow Donor Program Jan 31, 2025 | Compensation for services other than consulting (speaking, faculty) | $400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $48,503 in research payments for these studies, mostly to the institutions running them.
- A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplant…
National Marrow Donor Program - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. · Terminated · NCT04161885 - M19-063 - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. - Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Daiichi Sankyo Inc. · Active, not recruiting · NCT06578247
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.